Cooling caps designed to reduce hair loss in women undergoing chemotherapy for breast cancer (also known as alopecia) have been available internationally for decades but the FDA has only now, for the first time, cleared a scalp-cooling device for the U.S. market. Concerns about safety, efficacy and reimbursement have limited the availability of the technology for U.S. patients.

After leading 10 of its portfolio companies to exit in the past three years for a total enterprise value of almost €3 billion, European venture capital firm Sofinnova Partners is now armed with a new €300 million (US$328.7 million) fund to support a new stream of early stage companies. The firm blew past its initial fund target of €250 million and now has a total of €1.5 billion under management.

Competition is intensifying in the transcatheter aortic valve replacement (TAVR) market, but Edwards Lifesciences Corp. (Irvine, Calif.) (NYSE: EW) executives assured investors Wednesday the company is not resting on its TAVR laurels and still expects double-digit growth from its transcatheter heart valve therapy (THVT) business in 2016.

After leading 10 of its portfolio companies to exit in the past three years for a total enterprise value of almost €3 billion, European venture capital firm Sofinnova Partners (Paris) is now armed with a new €300 million fund to support a new stream of early-stage companies. The firm blew past its initial fund target of €250 million and now has a total of €1.5 billion ($1.6 billion) under management.

Arterys Inc. (San Francisco), a new medical imaging firm, has launched a cloud-based machine learning platform designed to deliver fast visualization and quantification with automatic analysis. The first application of the Arterys system is in the cardiovascular space, with the intention of enabling clinical visualization and quantification of blood flow inside the body.